Search Clinical Trials
Below please find a list of studies actively recruiting volunteers at one of the following GHUCCTS institutions: Georgetown University, Howard University, MedStar Health Research Institute, or Washington DC VA Medical Center. Please enter your search criteria below to help find a study for you. If you have any questions, please email us or call us at 301-560-2963.
397 matching studies
| Sponsor Condition of Interest |
|---|
|
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC1
Merck Sharp & Dohme LLC
Lung Neoplasm Malignant
The main goals are after treatment given before surgery, to measure the number of people
who have no signs of cancer cells in tumors and lymph nodes removed during surgery; and
to learn about whether the cancer gets smaller or goes away by measuring the number of
people with a certain number of liv1 expand
The main goals are after treatment given before surgery, to measure the number of people who have no signs of cancer cells in tumors and lymph nodes removed during surgery; and to learn about whether the cancer gets smaller or goes away by measuring the number of people with a certain number of living cancer cells in the tumor removed during surgery. Type: Interventional Start Date: Mar 2025 |
|
SIMPLAAFY Clinical Trial
Boston Scientific Corporation
Atrial Fibrillation
Stroke
Bleeding
The primary objective is to demonstrate the safety and effectiveness of two monotherapy
regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN
FLX Pro device in a commercial clinical setting. expand
The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting. Type: Interventional Start Date: Oct 2024 |
|
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cance1
NRG Oncology
Anatomic Stage IV Breast Cancer AJCC v8
Metastatic Breast Carcinoma
Metastatic Digestive System Carcinoma
Metastatic Lung Non-Small Cell Carcinoma
Metastatic Malignant Neoplasm in the Brain
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery
(FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer
that has spread from where it first started to the brain. Radiation therapy uses high
energy x-rays to kill tumor cells and1 expand
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain. Type: Interventional Start Date: Dec 2024 |
|
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Partici1
Celgene
Lymphoma, Follicular
The purpose of this study is to assess the efficacy and safety of golcadomide in
combination with rituximab in participants with newly diagnosed advanced stage Follicular
Lymphoma (FL). expand
The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL). Type: Interventional Start Date: Aug 2024 |
|
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Prev1
H. Lundbeck A/S
Migraine
The purpose of this trial is to determine which doses of Lu AG09222 are recommended to
help prevent migraines. People who join this trial have already tried 1 to 4 other
available medications to prevent their migraines, but these medications have not helped
them. expand
The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 1 to 4 other available medications to prevent their migraines, but these medications have not helped them. Type: Interventional Start Date: Apr 2024 |
|
Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD
Washington D.C. Veterans Affairs Medical Center
Chronic Kidney Diseases
Primary Objective:To study podocyte specific injury markers in African American Veterans
with non-diabetic kidney disease(NDKD), on empagliflozin therapy.
Primary Endpoint: Assess the effect of Empagliflozin on podocyte-specific proteins in
exosomes isolated from subjects' urine, such as nephrin,1 expand
Primary Objective:To study podocyte specific injury markers in African American Veterans with non-diabetic kidney disease(NDKD), on empagliflozin therapy. Primary Endpoint: Assess the effect of Empagliflozin on podocyte-specific proteins in exosomes isolated from subjects' urine, such as nephrin, podocalyxin and Wilms'Tumor (WT-1) protein. Secondary Objective: 1. Correlate changes in exosome-based podocyte specific proteins with standardized biomarkers of kidney injury including urine albumin/creatinine ratio (ACR) and estimated GFR. 2. Correlate systemic inflammatory markers (focusing on vascular and endothelial function) that are already established such as interleukins (IL1, IL6, IL-12) , hs-CRP and arterial stiffness measures with urine exosome-based podocyte protein estimation. 3. Correlate urine podocyte-specific protein markers with APOL1 mRNA expression levels in blood mononuclear cells (MNC) Type: Interventional Start Date: Feb 2024 |
|
Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Si1
Daniel Merenstein
Sinus Infection
Acute Sinusitis
Sinus infections are sometimes treated with oral antibiotics or nasal steroid sprays,
while some patients get better on their own. Some patients may wait a few days or use
common over-the-counter remedies to see if their symptoms improve without further
treatment. Sometimes this is enough to help p1 expand
Sinus infections are sometimes treated with oral antibiotics or nasal steroid sprays, while some patients get better on their own. Some patients may wait a few days or use common over-the-counter remedies to see if their symptoms improve without further treatment. Sometimes this is enough to help patients wait a few days to see if their infection clears up without needing to use antibiotics or nasal steroid sprays. The overall goal of this clinical trial to see which specific groups of patients benefit more from which intervention or combination of intervention, and which improve with supportive care alone. Type: Interventional Start Date: Nov 2023 |
|
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Dox1
Hoffmann-La Roche
Large B-Cell Lymphoma
The purpose of this study is to compare the efficacy and safety of glofitamab in
combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and
prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated
CD20-positive large B-cell lymphoma (LBCL). expand
The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL). Type: Interventional Start Date: Sep 2023 |
|
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiop1
Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of
BMS-986278 in participants with Idiopathic Pulmonary Fibrosis. expand
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis. Type: Interventional Start Date: Sep 2023 |
|
Nectero EAST System Clinical Study
Nectero Medical, Inc.
Abdominal Aortic Aneurysm
The purpose of this randomized clinical trial is to treat patients with small to
mid-sized abdominal aortic aneurysms (AAA), maximum diameter of 3.5 cm to 5.0 cm, using a
locally delivered, single-dose endovascular treatment. The main question the study aims
to answer is to demonstrate efficacy of1 expand
The purpose of this randomized clinical trial is to treat patients with small to mid-sized abdominal aortic aneurysms (AAA), maximum diameter of 3.5 cm to 5.0 cm, using a locally delivered, single-dose endovascular treatment. The main question the study aims to answer is to demonstrate efficacy of the product for stabilization of these small to mid-sized AAA.The study will compare the treatment group to the typical standard of care for these patients, surveillance. All subjects will be followed at designated intervals at 30/60 days, 6, 12, 18 and 24 months with continued follow-up annually for up to 5 years. Type: Interventional Start Date: Oct 2023 |
|
Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure an1
Versantis AG
Acute-On-Chronic Liver Failure
Ascites
A Phase 2, multi-center, randomized, controlled, open-label study to evaluate the effects
of the intraperitoneal, liposomal formulation VS-01 in patients with an acute episode of
hepatic and/or extrahepatic organ dysfunctions and failures in the presence of liver
cirrhosis (Acute-on-Chronic Liver F1 expand
A Phase 2, multi-center, randomized, controlled, open-label study to evaluate the effects of the intraperitoneal, liposomal formulation VS-01 in patients with an acute episode of hepatic and/or extrahepatic organ dysfunctions and failures in the presence of liver cirrhosis (Acute-on-Chronic Liver Failure, ACLF) and accumulation of fluid in the abdominal cavity (ascites) Type: Interventional Start Date: Jul 2023 |
|
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo1
Hoffmann-La Roche
Metastatic Breast Cancer
This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo
(pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with
placebo in combination with Phesgo, as maintenance therapy, after induction therapy in
participants with previously untreated1 expand
This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with previously untreated HER2-positive advanced breast cancer (ABC). Type: Interventional Start Date: Sep 2023 |
|
The GORE® VIAFORT Vascular Stent Iliofemoral Study
W.L.Gore & Associates
Venous Thromboses
Venous Disease
Venous Leg Ulcer
Venous Stasis
Venous Ulcer
This study is a prospective, non-randomized, multicenter, single-arm, clinical study to
evaluate the performance, safety and efficacy of the GORE® VIAFORT Vascular Stent for
treatment of symptomatic iliofemoral venous obstruction. expand
This study is a prospective, non-randomized, multicenter, single-arm, clinical study to evaluate the performance, safety and efficacy of the GORE® VIAFORT Vascular Stent for treatment of symptomatic iliofemoral venous obstruction. Type: Interventional Start Date: Mar 2023 |
|
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants1
Janssen Research & Development, LLC
Advanced or Metastatic Colorectal Cancer
The purpose of this study is to assess the anti-tumor activity of amivantamab as a
monotherapy (Cohorts A, B, and C), to characterize the safety of amivantamab when added
to standard-of care (SoC) chemotherapy in participants with metastatic colorectal cancer
(mCRC) (Ph2 cohorts), and to assess the1 expand
The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to characterize the safety of amivantamab when added to standard-of care (SoC) chemotherapy in participants with metastatic colorectal cancer (mCRC) (Ph2 cohorts), and to assess the recommended phase 2 combination dose (RP2CD) of amivantamab when added to SoC chemotherapy (Ph1b cohorts). Type: Interventional Start Date: Jul 2022 |
|
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence1
NRG Oncology
Stage I Breast Cancer
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy
results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor
recurrence (IBTR) compared to breast conservation with breast radiation and endocrine
therapy. expand
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy. Type: Interventional Start Date: Jun 2021 |
|
Transcutaneous Tibial Nerve Stimulation for Spinal Cord Injury Neurogenic Bladder
The University of Texas Health Science Center, Houston
Spinal Cord Injuries
The purpose of this study is to determine if electric stimulation to the leg, called
transcutaneous tibial nerve stimulation (TTNS), can improve bladder outcomes in acute
spinal cord injury. expand
The purpose of this study is to determine if electric stimulation to the leg, called transcutaneous tibial nerve stimulation (TTNS), can improve bladder outcomes in acute spinal cord injury. Type: Interventional Start Date: Jun 2020 |
|
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell D1
Agios Pharmaceuticals, Inc.
Sickle Cell Disease
The main purpose of this study is to compare the effect of tebapivat versus placebo on
anemia and to detect a dose-response for hemoglobin (Hb) response in participants with
SCD. expand
The main purpose of this study is to compare the effect of tebapivat versus placebo on anemia and to detect a dose-response for hemoglobin (Hb) response in participants with SCD. Type: Interventional Start Date: May 2025 |
|
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With M1
Novartis Pharmaceuticals
Hidradenitis Suppurativa
The purpose of this study is to establish the efficacy, safety, and tolerability of
remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate
to severe hidradenitis suppurativa (HS). expand
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS). Type: Interventional Start Date: Jan 2025 |
|
Paraffin Wax and Exercise Prospective
Medstar Health Research Institute
Burn
Scar
Exercise Therapy
This study is being done to test if paraffin wax can be used to improve the range of
motion and function for scars across joints when used in combination with scar
rehabilitation therapy sessions. For those randomized to receive it, the paraffin wax
will be used alongside the participants' exercise1 expand
This study is being done to test if paraffin wax can be used to improve the range of motion and function for scars across joints when used in combination with scar rehabilitation therapy sessions. For those randomized to receive it, the paraffin wax will be used alongside the participants' exercise therapy treatments. Currently, treatments that are used in addition to rehabilitation therapy for increasing range of motion across joints in the burn population are limited. By getting more information about how paraffin wax may or may not work, patients in the future that have scars may be able to be helped. Type: Interventional Start Date: Jan 2025 |
|
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
Medtronic Cardiovascular
Aortic Stenosis
The purpose of this study is to generate clinical evidence on valve safety and
performance in subjects treated by redo Transcatheter Aortic Valve Replacement (TAVR). expand
The purpose of this study is to generate clinical evidence on valve safety and performance in subjects treated by redo Transcatheter Aortic Valve Replacement (TAVR). Type: Observational Start Date: Feb 2025 |
|
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-li1
Janssen Research & Development, LLC
Colorectal Neoplasms
The purpose of this study is to compare how long the participants are disease-free
(progression-free survival) when treated with amivantamab and chemotherapy with
5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin
(mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folin1 expand
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus cetuximab and mFOLFOX6 or FOLFIRI in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)/ Neuroblastoma RAS viral oncogene homolog (NRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) wild type (WT) unresectable or metastatic left-sided colorectal cancer. Type: Interventional Start Date: Oct 2024 |
|
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
Verona Pharma plc
Non-cystic Fibrosis Bronchiectasis
This study is a randomized, double-blind, placebo-controlled study designed to assess the
efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily
via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with
non-cystic fibrosis bronchiectasi1 expand
This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE). Type: Interventional Start Date: Sep 2024 |
|
ADVENT Post Approval Study
Boston Scientific Corporation
Paroxysmal Atrial Fibrillation
The ADVENT Post Approval Study (PAS) is a prospective, global, multicenter, observational
study. expand
The ADVENT Post Approval Study (PAS) is a prospective, global, multicenter, observational study. Type: Observational Start Date: Sep 2024 |
|
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
Biohaven Therapeutics Ltd.
Focal Epilepsy
The purpose of this study is to determine whether BHV-7000 is effective in the treatment
of refractory focal epilepsy. expand
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy. Type: Interventional Start Date: May 2024 |
|
TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)
P+F Products + Features USA Inc.
Tricuspid Regurgitation
Tricuspid Valve Disease
The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid
valve replacement system, which includes the TricValve® Transcatheter Bicaval Valve for
superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena
cava (IVC). The TricValve® Transca1 expand
The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve replacement system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The TricValve® Transcatheter Bicaval Valves are pre-mounted into the TricValve® Delivery System which is used for percutaneous access and delivery of the TricValve® Transcatheter Bicaval Valve in the vena cava. The system is a single use, sterile device compatible with all the valve sizes. The prostheses are implanted percutaneously into the inferior and superior vena cava without disturbing the native tricuspid valve. The device is made of bovine pericardium leaflets sutured on a nitinol self-expanding stent system. Type: Interventional Start Date: Jul 2024 |